Get started
Author

Ekaterina Gresko

NDR Kinase Is Activated by RASSF1A/MST1 in Response to Fas Receptor Stimulation and Promotes Apoptosis
2008 · Anton Vichalkovski, Ekaterina Gresko, et al. · Current Biology · 162
PDF
PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage
2010 · A Vichalkovski, E Gresko, et al. · Oncogene · 129
Phosphorylation-Dependent Control of Pc2 SUMO E3 Ligase Activity by Its Substrate Protein HIPK2
2006 · Ana Roscic, Andreas Möller, et al. · Molecular Cell · 129
PDF
Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)
2012 · Hatem A. Azim, Otto Metzger-Filho, et al. · Breast Cancer Research and Treatment · 75
Autoregulatory control of the p53 response by caspase‐mediated processing of HIPK2
2006 · Ekaterina Gresko, Ana Roscic, et al. · The EMBO Journal · 71
PDF
PML tumor suppressor is regulated by HIPK2-mediated phosphorylation in response to DNA damage
2008 · E Gresko, S Ritterhoff, et al. · Oncogene · 50
Covalent modification of human homeodomain interacting protein kinase 2 by SUMO-1 at lysine 25 affects its stability
2005 · Ekaterina Gresko, Andreas Möller, et al. · Biochemical and Biophysical Research Communications · 49
Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression
2003 · Andreas Möller, Hüseyin Sirma, et al. · Oncogene · 43
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
2018 · Stephan Stilgenbauer, Veronique Leblond, et al. · Leukemia · 36
PDF
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study
2018 · Véronique Leblond, Melih Aktan, et al. · Haematologica · 25
Expression Profiles of Androgen Independent Bone Metastatic Prostate Cancer Cells Indicate Up-regulation of the Putative Serine-threonine Kinase Gs3955
2004 · MARCO BISOFFI, IRENA KLIMA, et al. · The Journal of Urology · 14
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
2019 · Francesc Bosch, Guy Cantin, et al. · Leukemia · 13
PDF
Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials
2025 · Ana de Vera, Paula R Clemens, et al. · Steroids · 11
Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy
2026 · Hanns Lochmüller, Hernan Gonorazky, et al. · Journal of Neurology · 4
PDF
Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A
2023 · Flora Peyvandi, Cristina Tarango, et al. · Blood · 3
PDF
PB0201 Efanesoctocog Alfa Versus Extended Half-Life Factor VIII Therapies for Prophylaxis in Adolescents and Adults with Severe Hemophilia A: A Matching-Adjusted Indirect Comparison and Meta-Analysis
2023 · R. Klamroth, P. Guyot, et al. · Research and Practice in Thrombosis and Haemostasis · 2
Vamorolone Safety, Pharmacokinetics, and Exploratory Efficacy in Duchenne Muscular Dystrophy
2026 · Jean K. Mah, Hernan D. Gonorazky, et al. · Neurology · 1
PDF
Plain language summary of vamorolone for boys with Duchenne muscular dystrophy age 7 to less than 18 years
2026 · Hanns Lochmüller, Hernan Gonorazky, et al. · Figshare
Plain language summary of vamorolone for boys with Duchenne muscular dystrophy age 7 to less than 18 years
2026 · Hanns Lochmüller, Hernan Gonorazky, et al. · Future Neurology
PDF
2.60P Decoupling growth and loss of ambulation in Duchenne muscular dystrophy (DMD): Long-term outcomes with Vamorolone
2026 · Giovanni Baranello, Erik H. Niks, et al. · Neuromuscular Disorders
2.67P Primary results of the US expanded access protocol (EAP) study in vamorolone-treated DMD boys
2026 · Amy Harper, Nancy Kuntz, et al. · Neuromuscular Disorders
Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Interim Analysis in Paediatric Patients from the 24-Month, Prospective, Non-Interventional B-MORE Study
2025 · H Glosli, I Wieland, et al. · Hämostaseologie
Assessment of Measures to Reduce Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab in the GREEN Study
2016 · Francesc Bosch, Robin Foà, et al. · Blood
P2-18-01: The Magnitude of Trastuzumab Benefit in HER2−Positive (HER2+) Lobular Breast Carcinoma (BC): Results of a HERA Trial Sub-Group Analysis.
2011 · O Metzger, M Procter, et al. · Cancer Research
P1-12-01: Pregnancy during and Following Adjuvant Trastuzumab in Patients with HER2−Positive Breast Cancer: An Analysis from the HERA Trial (BIG 01-01).
2011 · HA Azim, O Metzger-Filho, et al. · Cancer Research
Works count: 25
Citation count: 817
H-index: 12
I10-index: 13
Year
Topic
Type